ZoBio and Domainex partner to support FORMA Therapeutics’ drug discovery programs15 December 2014 Dutch company ZoBio and Cambridge-based Domainex Ltd have announced a collaboration with US company FORMA Therapeutics to provide NMR-based structural biology services for a substantial panel of FORMA drug targets. The goal of the collaboration is to use ZoBio’s expertise in protein nuclear magnetic resonance (NMR) to elucidate the molecular basis for compound-target interaction, to complement ongoing X-ray crystallography approaches. NMR is currently the only alternative to crystallography capable of elucidating atomic resolution, 3D structural information. Under the agreement, ZoBio will design and express protein variants suitable for structural studies, to support FORMA’s oncology drug discovery research. In addition, Domainex will apply its Combinatorial Domain Hunting technology to generate suitable protein variants for a selection of particularly challenging targets, not previously amenable to structural studies. Successful targets from the joint ZoBio/Domainex effort will be used for subsequent NMR structural biology studies. Source: Domainex |
|||